Lupus Nephritis News Archive

Vitamin D Doesn't Improve Interferon Response in Lupus Patients

Vitamin D Doesn't Improve Interferon Response in Lupus Patients

No change in interferon signature in vitamin D-deficient patients, those with vitamin D repletion.

FCGR3B Copy Number Loss Increases Lupus Nephritis Risk

FCGR3B Copy Number Loss Increases Lupus Nephritis Risk

Increased risk of systemic lupus erythematosus, lupus nephritis with copy number loss, not gain.

Proteinuria Levels Predict Long-Term Renal Outcomes in Lupus Nephritis

Proteinuria Levels Predict Long-Term Renal Outcomes in Lupus Nephritis

Urinary red blood cells undermine a composite prediction of renal outcome.

Mycophenolate Mofetil Offers No Advantage in Lupus Nephritis

Mycophenolate Mofetil Offers No Advantage in Lupus Nephritis

New study also provides evidence that an early proteinuria decrease is a strong predictor of good long-term outcome.

Minorities, Uninsured Lack Care of ESRD in Lupus Nephritis

Minorities, Uninsured Lack Care of ESRD in Lupus Nephritis

Minority race/ethnicity and lack of private insurance associated with inadequate care in U.S.

Lupus Nephritis ESRD Rates Stable

Lupus Nephritis ESRD Rates Stable

The risk of end-stage renal disease in patients with systemic lupus erythematosus may even be declining, but outcomes differ by race.

Over 100,000 Medicare Patients May Suffer from Glomerulonephritis

Over 100,000 Medicare Patients May Suffer from Glomerulonephritis

The condition appears to be associated with high hospitalization and death rates, researchers reported.

Three Drug Combo Beneficial in Lupus Nephritis Patients

Three Drug Combo Beneficial in Lupus Nephritis Patients

Half of those lupus nephritis patients taking three medications achieved full remission.

Potential Plant-Derived Lupus Nephritis Treatment Has Few Side Effects

Potential Plant-Derived Lupus Nephritis Treatment Has Few Side Effects

A plant-based compound could provide a new treatment for lupus nephritis with fewer side effects.

Mortality in Lupus Patients Does Not Differ By Dialysis Type

Mortality in Lupus Patients Does Not Differ By Dialysis Type

Large study looked at matched pairs of lupus patients with renal disease starting dialysis with hemodialysis or peritoneal dialysis.

Kidney Disease Significantly Reduces Life Expectancy in SLE

Kidney Disease Significantly Reduces Life Expectancy in SLE

With systemic lupus erythematosus, kidney disease reduces life expectancy an average of 15 years

Kidney Involvement, High Anti-dsDNA Predict Lupus Flares

Kidney Involvement, High Anti-dsDNA Predict Lupus Flares

Predictors of moderate-severe SLE flare at week 52 identified using three indicators

Proteinuria Decline Linked to Improved Lupus Nephritis Outcomes

A 50% or greater reduction in proteinuria after six months of treatment for severe lupus nephritis predicted better 15-year renal survival.

Lupus Nephritis Need Not Prevent Renal Transplants

Lupus nephritis patients can be good candidates if their disease is quiescent for at least one year prior to surgery.

Systemic Lupus Erythematosus Flares Occur Despite Dialysis

SLE patients with renal failure often continue to experience flares, but most commonly these are serologic rather than clinical.

Abnormal SLE Serology Need Not Bar Pregnancy

If a lupus patient has never had renal disease, pregnancy, in and of itself, is not likely to increase that risk.

Proteinuria Recovery Heads Off LN Comorbidities

Even partial recovery in lupus nephritis patients lowers the risk of needing dialysis or a kidney transplant.

Lupus Nephritis Patient Genotype May Not Predict MMF Response

Lupus Nephritis Patient Genotype May Not Predict MMF Response

Effects of MMF may be influenced by the pathogenesis and/or cellular micro-environments unique to each disease process.

New Lupus Nephritis Guidelines Issued

The American College of Rheumatology (ACR) has issued new guidelines for screening, treating, and managing lupus nephritis (LN), including methods of identifying kidney disease, newer therapies, and pregnant patient care.

Rituximab Ineffective as Lupus Nephritis Add-On Therapy

Rituximab Ineffective as Lupus Nephritis Add-On Therapy

Adding rituximab to mycophenolate mofetil and corticosteroids does not improve outcomes in patients with lupus nephritis (LN), according to a study.

Black Race Worsens Transplant Outcomes

Black race is associated with worse renal transplant outcomes among patients with lupus nephritis and focal segmental glomerulosclerosis (FSGS), according to two studies presented at Kidney Week, the annual meeting of the American Society of Nephrology.

MMF Found Superior for Lupus Nephritis

Mycophenolate mofetil (MMF) is more effective than azathioprine as maintenance therapy for patients with active lupus nephritis (LN) who responded to induction therapy, researchers reported.

Abatacept May Benefit Some Lupus Nephritis Patients

CHICAGO—Adding abatacept to mycophenolate mofetil (MMF) and steroids does not significantly improve the time to complete renal response in patients with lupus nephritis (LN), according to the findings of a 12-month study presented at the 2011 American College of Rheumatology annual meeting.

Vascular Biomarkers May Help Predict Lupus Nephritis Flares

CHICAGO—Vascular biomarkers may forecast impending flare or flare outcome in patients with lupus nephritis (LN), according to researchers in New York.

Biopsies May Predict Renal Outcomes in Patients with Lupus Nephritis

Biopsies May Predict Renal Outcomes in Patients with Lupus Nephritis

CHICAGO—Certain features at the time of renal biopsy are associated with a particular class of lupus nephritis (LN) and may independently predict good renal outcomes, according to a new Canadian study presented at the 2011 American College of Rheumatology Annual Scientific Meeting.

Prolonged Immunoadsorption Eases Lupus Nephritis

ATLANTA—Prolonged immunoadsorption (IAS) decreases proteinuria and leads to sustained stabilization of lupus nephritis in patients with highly active systemic lupus erythematosus (SLE), according to long-term results of a small Austrian study. The treatment did not result in tumors, anaphylaxis, or orthostatic events.

Big Drop in Lupus Nephritis Deaths Documented

ATLANTA—Mortality rates from lupus nephritis have decreased significantly since 1975 but have leveled off over the past 10 years, British researchers found.

Earlier Rituximab Better for Lupus Nephritis Patients

ATLANTA—Lupus nephritis patients who receive rituximab earlier in the course of their disease rather than later have better outcomes, new findings suggest.

Regimen May Improve Lupus Nephritis Care

ATLANTA—Enteric-coated mycophenolate sodium (EC-MPS) in combination with steroids is a viable therapy for lupus nephritis, according to an Italian study presented at the American College of Rheumatology annual meeting.

Low-Dose Combination May Be Effective for Refractory Lupus Nephritis

ATLANTA—A low-dose combination of mycophenolate mofetil (MMF) and tacrolimus (TAC) may be a viable option for treating refractory lupus nephritis, according to a new study by Chinese investigators.

Kidney Transplants Generally Safe for Lupus Patients

Contrary to previous studies, lupus patients who receive kidney transplants rarely develop lupus nephritis in their new allograft, according to a study presented at ASN's Renal Week conference.

Rituximab Eases Lupus Nephritis

Rituximab is an effective treatment for lupus nephritis that enables reductions in maintenance steroids, data show.

Active Lupus Nephritis Raises Pregnancy Risks

Pregnant patients with active lupus nephritis have a higher incidence of maternal and fetal complications compared with patients who have systemic lupus erythematosus (SLE) without renal involvement, researchers reported in Lupus (2009;18:342-347).

In SLE, Renal Damage Is No. 1 Death Predictor

SAN FRANCISCO—Preventing renal damage in patients with systemic lupus erythematosus (SLE) may be critical to lowering their mortality rate, according to a new report.

Drugs Comparable for Adolescent Lupus Nephritis

SAN FRANCISCO—Lupus nephritis (LN) in adolescents responds similarly to mycophenolate mofetil (MMF) and IV cyclophosphamide, according to data reported at the American College of Rheumatology (ACR) annual meeting here.

Renal Flares Can Hike Medical Costs

SAN FRANCISCO—Patients with lupus nephritis (LN) who experience renal flares incur nearly double the direct medical costs over one year compared with those who not have flares, data suggest.

Incidence of Lupus-Nephritis-Related ESRD Highest in Blacks

SAN FRANCISCO—The incidence of end-stage renal disease (ESRD) due to lupus nephritis (LN) rose significantly in the United States from 1995 to 2004, according to new study data presented here at the American College of Rheumatology annual meeting. The incidence was significantly higher among African Americans and women.

Lupus Nephritis Recurrence After Renal Transplant

SAN FRANCISCO—Lupus nephritis recurrence (LNR) in renal transplant recipients with systemic lupus erythematosus (SLE) does not have an adverse impact on allograft or patient survival rates, according to the largest analysis of its kind to be reported.

Anti-Malaria Drug May Prevent SLE Renal Damage

SAN FRANCISCO—Hydroxychloroquine, a low-risk and inexpensive generic drug originally used to treat malaria, may help prevent kidney damage in patients with systemic lupus erythematosus (SLE), according to new study findings presented here at the American College of Rheumatology (ACR) annual scientific meeting.

ACE Inhibitor Use Eases SLE

ACE inhibitor use delays development of renal involvement in patients with systemic lupus erythematosus (SLE).

Rituximab May Not Halt Progression to ESRD

Rituximab May Not Halt Progression to ESRD

BOSTON—Rituximab is highly effective for treating resistant systemic lupus erythematosus (SLE), but, in certain patients, the medication does not prevent progression to end-stage renal disease (ESRD), British researchers conclude.

Traditional Lupus Nephritis Regimen Best

BOSTON—The traditional cyclophosphamide regimen for lupus nephritis recommended by the National Institutes of Health (NIH) is superior to high-dose immunoablative cyclophosphamide, a recent study suggests.

SLE Nephritis is More Common in Males

BOSTON—Kidney involvement stemming from systemic lupus erythematosus (SLE) may be more common in male than female patients, researchers reported at the annual meeting of American College of Rheumatology.

24-Hour Urine Collection May Be Avoidable

24-Hour Urine Collection May Be Avoidable

BOSTON—It may be possible to get accurate urine protein excretion estimates in lupus nephritis patients in three or 12 hours instead of 24, according to researchers at Johns Hopkins University in Baltimore.

Race, Ethnicity, and SLE Drugs

Race, Ethnicity, and SLE Drugs

BOSTON—Among the various racial and ethnic groups in the United States, Hispanics have the worst response to treatment for proliferative nephritis due to systemic lupus erythematosus (SLE), data show.

Renal Function at Biopsy Is Key

WASHINGTON, D.C.—The best predictor of outcome in patients with lupus nephritis is kidney function at the time of renal biopsy, supporting the need for early diagnosis and treatment, researchers reported here at the American College of Rheumatology annual meeting.

NO Higher in Proliferative Nephritis

Systemic nitric oxide (NO) levels are elevated in patients with proliferative lupus nephritis, researchers found. The association is independent of renal elimination of nitrate and nitrite (NOx), a measure of NO production.

Medication Relieves Severe Lupus Nephritis

Rituximab (Rituxan), a biologic agent used to treat B-cell non-Hodgkin's lymphoma, may offer a promising option for treating severe membranous lupus nephritis (MLN), according to Swedish researchers.

Any Lupus Nephritis Remission Helps

Even partial remission of lupus nephritis may be associated with better patient survival and a reduced risk of progressing to end-stage renal disease (ESRD).

A Novel Biomarker for Lupus Nephritis

Researchers say they have discovered a novel biomarker for renal activity in patients with lupus nephritis. The marking, a cytokine called TWEAK, can be measured with a simple urine test.

Sign Up for Free e-newsletters